One of the most important principles of sound investment management is staying on top of what’s happening in the world and how those events affect finances. Conditions change quickly, and keeping up-to-date on developments and trends can be challenging. The team of experts producing IWB have been advising Canadian investors for over 25 years.

Edited and Published by Gordon Pape. Associate Editor: Richard Croft

With Gavin Graham, Ryan Irvine, Glenn Rogers, Shawn Allen, Adam Mayers, Paul Bamford & Michael Corcoran.

Recent Issues

Recent Updates

Alphabet Inc. (NDQ: GOOGL)

The firm implemented a major restructuring in 2015 that created Alphabet as a holding company for Google (which includes Android, Chrome, and YouTube), Nest (home automation), Calico (anti-aging research), Fiber (high-speed Internet), Google Ventures (new company investments), Sidewalk Labs (city infrastructure), and Waymo (driverless cars). Other services include Google Maps, Google Play, AI, and cloud computing.

Hold


iShares U.S. Medical Devices ETF (NYSE: IHI)

This ETF was launched in 2006 and holds US manufacturers who make and distribute medical devices. The companies are the biggest names with the broadest global reach.

Hold


The Home Depot (NYSE: HD)

Home Depot was founded in 1978 and now has a total of more than 2,350 retail stores in all 10 provinces, all 50 US states, the District of Columbia, Puerto Rico, the US Virgin Islands, Guam, and Mexico. The company generated $159.5 billion in revenue in 2024. It employs approximately 470,000 workers.

Hold


Novo Nordisk A/S (NYSE: NVO)

Novo Nordisk A/S is a Danish multinational pharmaceutical company focused on diabetes care, medicines, and devices. Its main product is the drug semaglutide, which is used to treat diabetes under the brand name Ozempic. It markets a similar formulation for  weight loss under the brand name Wegovy.

Hold


Eli Lilly & Co. (NYSE: LLY)

Eli Lilly is a leading producer of a new type of diabetes/weight loss drug. Eli Lilly’s trade name for their drug is Mounjaro. It was approved in the US in 2022 for treatment of Type 2 diabetes and is expected to be approved as a weight-loss drug by year-end.

Buy